Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating restated by FinnCap in a report issued on Tuesday. They presently have a GBX 47 ($0.62) price target on the stock. FinnCap’s price target points to a potential upside of 57.98% from the company’s current price.

AGY has been the subject of several other research reports. Panmure Gordon restated a “buy” rating on shares of Allergy Therapeutics plc in a research report on Monday, September 18th. Numis Securities Ltd restated a “buy” rating and issued a GBX 45 ($0.59) target price on shares of Allergy Therapeutics plc in a research report on Friday, September 22nd.

Allergy Therapeutics plc (LON AGY) traded down GBX 0.50 ($0.01) during midday trading on Tuesday, reaching GBX 29.75 ($0.39). Allergy Therapeutics plc has a 52-week low of GBX 19.50 ($0.26) and a 52-week high of GBX 39.50 ($0.52).

TRADEMARK VIOLATION WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at

In related news, insider Tunde Otulana purchased 25,000 shares of Allergy Therapeutics plc stock in a transaction dated Wednesday, October 11th. The stock was bought at an average cost of GBX 51 ($0.67) per share, with a total value of £12,750 ($16,769.70).

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with's FREE daily email newsletter.